Astellas Pharma Gmbh

Kokusai Denshin Denwa Co., Ltd.

Kokusai Denshin Denwa Kabushiki Kaisha

Seldar Pharma Inc.

Yamanouchi Pharmaceutical Company Ltd.

Norio Seki

Daisuke Suzuki

Hiroshi Matsuda

Haruo Sakaguchi

Tsukasa Ishihara

Shu Yamamoto

Itsuro Shimada

Takafumi Shimizu

Kyoichi Maeno

Hiroyuki Hisamichi

Tomofumi Takuwa

Noriko Ishikawa

Fukushi Hirayama

Yuji Koga

Susumu Yamaki

Kousei Yoshihara

Hiroyuki Koshio

Yuzo Matsumoto

Keizo Sugasawa

Souichirou Kawazoe

Ryota Shiraki

Hiroyoshi Yamada

Yohtaro Yatsuzuka

Shunichiro Hachiya

Takeshi Shigenaga

Hisashi Mihara

Masaaki Hirano

Minoru Okada

Hiroyuki Moritomo

Yoshinao Iwamoto

Eiji Kawaminami

Akira Toyoshima

Jiro Fujiyasu

Hideo Ishihara

Ryutaro Wakayama

Toshiyuki Kusayama

Akira Okada

Junji Sato

Hiroshi Nagata

Hiroharu Wakabayashi

Kenji Negoro

Minoru Yasuda

Tadashi Terasaka

Chuichi Ota

Ken-Ichi Suzuki

Masahiro Neya

Daisuke Kaga

Yoshiyuki Tenda

Yoshimasa Imamura

Daisuke Sasuga

Masahiro Takeda

Tatsuya Zenkoh

Teruji Watanabe

Seiichiro Tabuchi

Hisashi Hayashida

Mamoru Tasaki

Kazunori Tsubaki

To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

Tetrahydroisoquinolin-1-one derivative or salt thereof

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Guanidine compound

Compounds of formula (I) defined herein exhibit VAP-1 inhibitory activity, and as a result, are useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention.

Glycine compound

[Problems] To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). [Means for Solving Problems] It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.

Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents

To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4'-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.

Diazepan derivatives or salts thereof

Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli. Means for Solution: Benzene derivatives or their salts having a characteristic chemical structure with a phenol ring and a benzene ring bonding to each other via an amide bond, in which the phenol ring further bonds to a benzene ring or a heteroaryl ring via an amide bond. They have an excellent effect of inhibiting the activated blood coagulation factor X, and especially have an excellent oral activity.

Benzene derivative or salt thereof

Provided is a pharmaceutical composition containing a propane-1,3-dione derivative as the active ingredient, particularly a GnRH receptor antagonist. Also, provided is a propane-1,3-dione derivative having a GnRH antagonistic effect.

Propane-1, 3-dione derivative

Propane-1,3-dione derivative

Growing community of inventors

Tokyo, Japan

Norio Seki